Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05377723 · ClinicalTrials.gov registry record · NA
Abdominal Scar Improvement in Microsurgical Breast Reconstruction
A NA study of Breast Reconstruction and Cicatrix, sponsored by Stanford University.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05377723: Active NA study of Breast Reconstruction and Cicatrix, sponsored by Stanford University.
NCT05377723 is a NA study of Breast Reconstruction and Cicatrix that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 30 participants, below the 392-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05377723, a NA study of Breast Reconstruction and Cicatrix, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Microsurgical breast reconstruction is most commonly performed with free abdominal flaps, which leave a long transverse lower abdominal scar. Due to tension across the incision, these scars frequently widen and hypertrophy. Hence, modalities that can reduce this tendency, thus, improving scar appearance are desirable. Here, we wish to investigate the impact of the Neodyne embrace device on postoperative abdominal scar appearance. The proposed study is novel in that it is the first RCT investigating the effect of the embrace device on scar appearance in the context of microsurgical breast reconstruction.
Primary Outcome
The primary endpoint is the difference between the assessments of the scar appearance for the treated as compared to the control incision sites. Incisions will be evaluated by an objective independent expert panel at six months post surgery. The panel will review close-up photographic records, taken at the 6 month study endpoint, of the control incision site and the treated incision site. The subject will complete the Scar Q questionnaire and both the investigator and the subject will complete t
Conditions Studied
Interventions
- DEVICE Neodyne Device
Study Locations (1)
California
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2026-04 |
| Phase | NA |
What the registry record for NCT05377723 still lists
NCT05377723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 392-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Breast Reconstruction appearing as the primary indexed condition, and to 1 intervention - of which Neodyne Device is the first listed.
NCT05377723 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05377723 about?
NCT05377723 is a clinical study titled "Abdominal Scar Improvement in Microsurgical Breast Reconstruction". Microsurgical breast reconstruction is most commonly performed with free abdominal flaps, which leave a long transverse lower abdominal scar. Due to tension across the incision, these scars frequently widen and hypertrophy. Hence, modalities that can reduce this tendency, thus, improving scar appear...
What is the current status of trial NCT05377723?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-10-31. Estimated completion is 2026-04.
What conditions does trial NCT05377723 study?
This clinical trial studies the following conditions: Breast Reconstruction, Cicatrix.
What interventions are being tested in trial NCT05377723?
The interventions under investigation include: Neodyne Device (DEVICE).
Who is sponsoring clinical trial NCT05377723?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05377723 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Reconstruction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05377723's enrollment target sits among peer trials
30 19th of 18 the lowest of 18 other Breast Reconstruction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Reconstruction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on Pain After Breast Reconstruction
RECRUITING · NA
-
Melodi Matrix™ in Breast Reconstruction
RECRUITING · NA
-
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
RECRUITING · NA
-
Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction
RECRUITING · NA
-
Pulsed Lavage in Implant-Based Breast Reconstruction
RECRUITING · NA
-
SAVE Trial: SAfe Opioid Use Video Education
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI